Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Change in Account Payables: 2016-2024

Historic Change in Account Payables for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to $146,000.

  • Mereo BioPharma Group's Change in Account Payables rose 77.84% to -$236,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$982,000, marking a year-over-year decrease of 438.62%. This contributed to the annual value of $146,000 for FY2024, which is 111.56% up from last year.
  • Per Mereo BioPharma Group's latest filing, its Change in Account Payables stood at $146,000 for FY2024, which was up 111.56% from -$1.3 million recorded in FY2023.
  • Over the past 5 years, Mereo BioPharma Group's Change in Account Payables peaked at $617,000 during FY2022, and registered a low of -$4.6 million during FY2020.
  • Over the past 3 years, Mereo BioPharma Group's median Change in Account Payables value was $146,000 (recorded in 2024), while the average stood at -$166,667.
  • In the last 5 years, Mereo BioPharma Group's Change in Account Payables spiked by 136.44% in 2022 and then slumped by 304.70% in 2023.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Change in Account Payables stood at -$4.6 million in 2020, then surged by 62.87% to -$1.7 million in 2021, then surged by 136.44% to $617,000 in 2022, then slumped by 304.70% to -$1.3 million in 2023, then surged by 111.56% to $146,000 in 2024.